DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

Information source: University of Chicago
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Seasonal Allergic Rhinitis

Intervention: mometasone furoate nasal spray (Drug); placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Chicago

Official(s) and/or principal investigator(s):
Robert M Naclerio, MD, Principal Investigator, Affiliation: University of Chicago


We hypothesize that those patients with purely seasonal allergic rhinitis will decongest better than those subjects with another cause contributing to their symptoms. These latter patients will not improve as well on an intranasal steroid as those who decongest well, potentially explaining the 60% response rate in prior studies.

Clinical Details

Official title: Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Primary outcome: Global Assessment

Secondary outcome:

Changes in RQLQ: Overall

Changes in RQLQ: Activity

Changes in RQLQ: Sleep

Changes in RQLQ: Non-Nasal/Eye

Changes in RQLQ: Practical

Changes in RQLQ: Nasal

Changes in RQLQ: Emotional

Changes in RQLQ: Eye


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria 1. Males and females between 18 and 60 years of age. 2. History of grass and/or ragweed allergic rhinitis. 3. Positive skin or RAST test to grass, trees and/or ragweed antigen. 4. Symptomatic at time of entry into study. Exclusion Criteria 1. Women of childbearing potential not using the contraception method(s) (Birth control pills, depo Provera, double barrier) as well as women who are pregnant or breastfeeding. 2. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease). 3. Use of any other investigational agent in the last 30 days. 4. Absence of nasal symptoms. 5. Smoking. 6. URI at the time of screening.

Locations and Contacts

University of Chicago, Chicago, Illinois 60637, United States
Additional Information

Starting date: April 2008
Last updated: January 21, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017